Egan M F, el-Mallakh R S, Suddath R L, Lohr J B, Bracha H S, Wyatt R J
Neuropsychiatry Branch, National Institute of Mental Health, Washington, DC.
Psychiatry Res. 1992 Aug;43(2):187-95. doi: 10.1016/0165-1781(92)90133-n.
Some patients with schizophrenia appear to have brain abnormalities, including enlarged third and lateral ventricles and reduced volumes of temporal lobe structures. These abnormalities could be attributed to a developmental abnormality or a neurodegenerative process. Neuron-specific enolase (NSE), a protein that is found primarily in neurons and neuroendocrine cells, has been used as an index of neuronal damage or degeneration. Levels of NSE in cerebrospinal fluid (CSF) and serum from 50 patients with acute and chronic schizophrenia were compared with those in normal and neurological control subjects. A double-antibody, solid phase iodinated radioimmunoassay was used to determine NSE levels. There was no evidence of elevated levels in patients with schizophrenia, whereas control subjects with neurological illnesses had increased levels of NSE in CSF. Because NSE is rapidly cleared from CSF, however, elevated levels could have been missed. Unmedicated patients tended to have lower levels than medicated patients.
一些精神分裂症患者似乎存在大脑异常,包括第三脑室和侧脑室扩大以及颞叶结构体积减小。这些异常可能归因于发育异常或神经退行性过程。神经元特异性烯醇化酶(NSE)是一种主要存在于神经元和神经内分泌细胞中的蛋白质,已被用作神经元损伤或退化的指标。将50例急性和慢性精神分裂症患者脑脊液(CSF)和血清中的NSE水平与正常人和神经疾病对照受试者的水平进行了比较。采用双抗体固相碘化放射免疫分析法测定NSE水平。精神分裂症患者没有证据表明NSE水平升高,而患有神经疾病的对照受试者脑脊液中的NSE水平升高。然而,由于NSE会迅速从脑脊液中清除,因此可能会遗漏升高的水平。未接受药物治疗的患者往往比接受药物治疗的患者水平更低。